Prevention of HIV/AIDS and STDs in Women Over Fifty
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03810170 |
Recruitment Status :
Completed
First Posted : January 18, 2019
Last Update Posted : January 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hiv Sexually Transmitted Diseases Aging | Behavioral: safe sex and HIV/STD prevention education via a website Other: written materials on safe sex | Phase 2 |
Older adult women (age 50+) account for almost a third of the U.S. HIV/AIDS population, and infection rates among this group are increasing. The overall goal of the proposed Phase II application is to develop a culturally-sensitive, gender-specific, and age-appropriate HIV prevention intervention for older women, especially African American and Latino women who are at disproportionally high risk for HIV/STD infection. The target population is the growing number of divorced/separated older women for whom interventions have not been developed and, due to cohort and social contextual factors, are likely unaware that they are at risk, and more likely than single (never married) women to forgo condom use. Building on Phase I and ARRA study results, the Phase II objectives are to create, test, and commercialize a positive psychology-based "SmartWeb" intervention to promote wellbeing and safe sex practices among culturally diverse older divorced or separated women who are dating or planning on dating. Specific Phase II Aims are: 1) Create the SmartWeb intervention; 2) Evaluate its effectiveness in a randomized controlled trial (RCT) of divorced/separated women over 50; and 3) Prepare marketing and commercialization plans for the SmartWeb intervention.
Consistent with Phase I objectives, i.e., developing content to address Stages 1-3 of the M-AARM theoretical model, the proposed Phase II includes new components to address M-AARM Stages 4-5. The Phase II is also responsive to Phase I evaluation findings, including the desire for mobile access, membership; video interviews with experts in women's health, positive aging, HIV/STD prevention in culturally diverse communities, safe sex negotiation strategies, and gray divorce; online community, and positive psychology- based self-efficacy and affect-boosting emails, as well as expanded versions of Phase I components to reinforce stages 1-3 of the M-ARRM theoretical model.
The investigators are supported in these efforts through partnerships in both Boston, MA and Columbia SC, the sites for the randomized controlled trial. Participating partners include those providing commercialization support (Global Protection Corp, USC Columbia Incubator, SC Launch, Moker CPCA), recruitment and marketing support in Boston (New England Association of HIV over 50, Massachusetts Department of Public Health Statewide Consumer Advisory Board on HIV/AIDS, Brigham & Women's Hospital Women's Health Center) and in Columbia (South Carolina Lieutenant Governor's Office on Aging, South Carolina HIV/AIDS Council, AID Upstate in South Carolina, Lowcountry AIDS Services, United Way Association of South Carolina, South Carolina Primary Care Association, Columbia Housing Authority in South Carolina, Palmetto AIDS Life Support Services), and content and technology development and support (University of South Carolina College of Social Work and Department of Computer Science and Engineering, South Carolina HIV/AIDS Council)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 331 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | randomized controlled trial |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Prevention of HIV/AIDS and STDs in Women Over Fifty |
Actual Study Start Date : | September 1, 2009 |
Actual Primary Completion Date : | June 30, 2018 |
Actual Study Completion Date : | June 30, 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: control
control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
|
Other: written materials on safe sex
2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics |
Experimental: intervention
intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
|
Behavioral: safe sex and HIV/STD prevention education via a website
website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education. |
- intention to engage in safe sex questionnaire [ Time Frame: 90 days ]A three-item intention to engage in safe sex practices instrument. Participants will answer 3 questions, validated for this population (Fisher et al., 1998; Mausbach et al., 2009), regarding their intentions to use protection during sex over the next two months (e.g., "I intend to always use condoms during vaginal sex with all of my partners during the next two months") Responses are on a 5-point Likert scale, 1 = "Very Untrue" and 5 = "Very True". The score ranges from 3 to 15. The higher score indicate better intention to engage in safe sex.
- safe sex self-efficacy questionnaire [ Time Frame: 90 days ]8-item Self-efficacy for Sexual Discussion Scale. Responses are on a 4-point scale, 1='disagree' and 4='agree'. The first two questions should be reversed when coding. Sum up the final score and the higher the score is indicate the higher self-efficacy for sexual discussion.
- HIV transmission knowledge questionnaire [ Time Frame: 90 days ]There are two questionnaires in this outcome: a 13-item modified HIV Sexual Transmission and Prevention Knowledge and a 15-item HIV/AIDS Knowledge and Attitudes Survey. Each correct answer get one point. The final score is the sum up of all the questions. Range from 0-28.
- perceived sexual/HIV risk questionnaire [ Time Frame: 90 days ]38-item Perceived Sexual Risks Scale. The self-assessment allows participants to evaluate the degree to which they may be at risk for engaging in behavior that exposes themselves to HIV. For each of the 38 items, participants choose from 'agree', 'undecided', or 'disagree' that best characterizes their option. Begin by giving scoring eighty points. Subtract one point for every undecided response. Subtract two points every time that participants disagreed with odd-numbered items or with item number 38. Subtract two points every time participants agreed with even-numbered items 2 through 36. Higher scores are more likely to engage in risky sexual activities.
- positive affect questionnaire [ Time Frame: 90 days ]4-item scale General Happiness Scale. A 4-item scale designed to measure subjective happiness. Each of item is completed by choosing one of 7 options that finish a given sentence fragment. Compute the mean across responses to all four questions; item #4 is reverse coded. The higher score indicate higher subjective happiness.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- divorced or separated women
- 50 years of age and older
- who are dating or thinking of dating in the near future
- HIV negative
- access to internet via computer or smartphone
- English primary language
Exclusion Criteria:
- currently married
- HIV positive
- participating in another research study or clinical trial
- do not own home computer with internet access or smartphone

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03810170
United States, Massachusetts | |
Environment and Health Group | |
Cambridge, Massachusetts, United States, 02138 |
Responsible Party: | Patricia Weitzman, Principal Investigator, Environment and Health Group, Inc. |
ClinicalTrials.gov Identifier: | NCT03810170 History of Changes |
Other Study ID Numbers: |
R44AG034707 ( U.S. NIH Grant/Contract ) |
First Posted: | January 18, 2019 Key Record Dates |
Last Update Posted: | January 18, 2019 |
Last Verified: | January 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
Sexually Transmitted Diseases Infection Virus Diseases Genital Diseases, Male Genital Diseases, Female |